Back to Agenda
Session 1 / Venue 1: Drug Development thorough Collaboration with ARO and Future - Part 1
Session Chair(s)
Fumitaka Nagamura, MD, PhD
Professor
The University of Tokyo, Japan
MHLW has started to provide budgetary support to 15 Core Clinical Research Centers nationwide since 2011. It also requests those centers to build a new infrastructure called ARO (Academic Research Organization) to conduct clinical trials by themselves. Each center has built an organization to suit their specialty and promoted some activities although their goals and strategies are various. Some organizations develop pharmaceutical products and medical devices for specific indications, some establish centers for phase 1 trials, some set up groups using networks. We expect you have a lot of questions on ARO. What kind of improvement did they implement who already introduced ARO? What kind of challenges do they face in particular? Is it possible for Academia to develop pharmaceutical products and medical devices? What is the role of researchers? How the collaboration among Industry and Regulatory has been facilitated? We will discuss these questions asked and issues and would like to find out common understanding to the basic question “what is ARO?”
Speaker(s)
Attempt by Chiba University
Hideki Hanaoka, MD, PhD
Chiba University Hospital, Japan
Attempt by National Cerebral and Cardiovascular Center
Haruko Yamamoto, MD, PhD
National Cerebral and Cardiovascular Center, Japan
Director, Department of Data Science
Attempt by Kyushu University
Yoichi Nakanishi, MD, PhD
Kyushu University, Japan
Professor and Director, Research Institute for Diseases of Chest
Attempt by National Cancer Center Hospital East
Toshihiko Doi, MD, PhD
National Cancer Center Hospital East, Japan
Deputy Director / Chief, Experimental Therapeutics
Have an account?